Global Blau Syndrome Market by Therapeutic Areas (Skin Rash, Inflammation), By Route of Administration (Oral, Parenteral, Topical), By End User (Hospitals, Home healthcare, Specialty clinics), By Distribution Channel (Hospital pharmacy, Online pharmacy, Retail pharmacy), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Blau Syndrome Market size is expected to be worth around USD 25.0 Million by 2033 from USD 7.9 Million in 2023, growing at a CAGR of 12.2% during the forecast period from 2024 to 2033.

A rare genetic disorder, Blau syndrome, also known as Arthrocutaneouveal granulomatosis is delineated by tissue damage and inflammation in the body parts such as in eyes, skin and joints. Inflammation of eyes(uveitis), skin rash, swelling of lymph nodes, joint pain and stiffness are some of the common symptoms, typically occurring during the toy age between 3-4 years. Other critical symptoms include fever, weight loss, vandalism to liver and kidneys.

Various diagnostic ways are involved in order to diagnose Blau syndrome, which involves physical exam, imaging and genetic testing. Joint pain and inflammation, skin rash, eye inflammation can be divulged through physical exam. For the identification of bone or joint abnormalities, imaging tests such as X-rays or MRI is employed. Furthermore, genetic testing is carried out to know the mutations in NOD₂ genes, which produces proteins responsible for immune responses.

The rising prevalence of rare genetic disorder and the clinical need to develop the therapeutic medications is likely to drive the market share of Blau syndrome. Several advancements in the health care industry of blau syndrome will impact in launching new product by the several manufacturers into the market, improving its demand along with availability of off-label drugs. However, lower awareness about the syndrome among developing nations can hamper the market dimensions.

Key Takeaways

• The oral segment is accounted to hold the large market share of 49.1% in 2023
• Hospital pharmacy dominates the entire distribution channel segment and is accounted to hold a large market share of 39.4% in 2023
• Hospital segment dominates the other end users and is accounted to hold a large market share of 64.2%
• The technological advancement in imaging techniques and development of new medications to propel the market shares.
• High cost of diagnostics and drugs and lack of professionals, can hamper the market expansion.
• North America has the largest patient pool for Blau syndrome and also represents the largest market share of 61.2%,

By Route of Administration

Majority of the children are prescribed with oral administration

Based on route of administration, the market in segmented into oral, parenteral, topical and others. The oral segment is accounted to hold the large market share of 49.1% in 2023, with a 13.1% CAGR. The reason for its dominance is, most of the children suffering from blau syndrome are prescribed the oral therapies for affected areas such as corticosteroids, immunosuppressant, tumour necrosis factor inhibitor, and thalidomide. Studies have found that thalidomide have strong immunomodulatory effect.

• In 2010, Japanese scholars found that thalidomide dramatically improved the symptoms of blau syndrome providing effective inhibition of severe inflammatory reactions in patients with NOD₂ related diseases.

Newer biologic oral medications that work to target specific areas of the immune system can also treat Blau syndrome. Examples of medications that a doctor prescribe to treat this condition includes Etanercept, Adalimumab, Kirenet, etc.

By Distribution Channel

Hospital pharmacy dominates due to systematic prescription decision

According to the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy. Hospital pharmacy dominates the entire distribution channel segment and is accounted to hold a large market share of 39.4% in 2023, and is expected to poise a substantial growth in the imminent years.

Although, many of the tasks of hospital pharmacy are similar to that of community pharmacy but there is a prominent difference such as increased interaction with prescribers and other health professionals, better access to medical records of patients and greater input in prescribing decisions about drugs and administration.

In addition to this, hospital pharmacies usually stock a large variety of medications, including those for specialized purposes that may only be indicated in a controlled medical setting.

By End User

Availability of required resources dominates the hospital segment.

By end user analysis, the market is ramified into hospitals, home healthcare and specialty clinics. Hospital segment dominates the other end users and is accounted to hold a large market share of 64.2%, with a hefty 11.2% CAGR. The paramount reason for hospitals being more preferred by patients to treat blau syndrome is the provision of systematic analysis and medication to suppress immune system for the reduction of inflammation, making the treatment safer and efficacious.

• According to a report, United States to generate highest revenue from hospitals, amounting to the US$ 1,436 billion in 2023.

Key segments

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

By End User

• Hospitals
• Home healthcare
• Specialty clinics

Market Driver

Increasing diagnostic procedures boosts the market growth

Numerous key players are making extensive investments in research activities to explore gene editing technologies, like transcription activator-like effector nucleases (TALENs), for targeting and repairing specific gene mutations that cause blau syndrome. The technological advancements in imaging techniques, such as introduction of Optical coherence tomography (OCT), helps for improving the diagnosis of diseases affecting the eyes.

The another technology to reveal noncaseating granulomas is skin biopsy, which is less invasive with higher accuracy rate. These emerging technologies drive the blau syndrome market.

New medications to narrow the suffering of Blau syndrome

The escalating usage of non-steroidal anti-inflammatory drugs such as ibuprofen, helps to dwindle joint inflammation and alleviate pain affiliated with arthritis and dermatitis. In addition to this, the worldwide adoption of disease modifying anti-rheumatic drugs for managing symptoms and preventing organ damage, is providing a profitable outlook for the market growth.

Market Restraints

High cost of medications and therapies

The elevated costs of medications and therapies employed for the treatment or diagnosis of Blau syndrome is presumed to retard the market dimensions during the forecast period 2024-2033. To illustrate, the cost of thalidomide oral capsule 50 mg is around the US$ 1,853 for a supply of 10 capsules.

In India, for diagnosis of eyes infected with blau syndrome the average diagnosis cost of Optical coherence tomography is 3,500 rupees. This elevating costs of medications or diagnosis are not affordable for the people in underdeveloped regions. Hence this increases chances of untreated blau syndrome among population.

Opportunities

Advancing treatment preferences

With the rise in number of blau syndrome worldwide, there is also increase in number of treatment alternatives. The usage of corticosteroids for the treatment of blau syndrome is associated with the occurrence of obstinate prognostics, signifying the use of immunosuppressant such as mycophenolate mofetil, methotrexate, or azathioprine. For this reason, these suppressants are widely used by patients, though variable degrees of efficacy have been witnessed.

In addition to this, operative interventions are also incorporated for the treatment of ocular diseases, along with this various inflammatory conditions are surgically operated. For instance, many patients opt for joint fusion procedures because of severe obstinate arthritis, thus, providing various opportunities for the pharmaceutical companies and hospitals to enlarge its market share.

Latest Trends

There are various emerging technologies to diagnose and treat symptoms of blau syndrome, these are as follow,

• Robotics: Canfield scientific, a New jersey based company, installed the first commercial Vectra WB360 whole body skin lesion mapping system, which is able to take 360-degree scan of the body to identify the lesions on skin. This helps to diagnose the skin related issues occurring in blau syndrome, making the treatment quick and effective.
• Launch of AMGEVITA: It is a medicine that acts on immune system to treat plaque psoriasis, rheumatoid arthritis, noninfectious uveitis, and polyarticular juvenile idiopathic arthritis and active enthesitis-related arthritis
• Optical Coherence Tomography: is an emerging technology for performing high resolution cross sectional imaging, making use of light instead of sound. This technology provides cross sectional images of tissue structure of eyes on micron scale in situ and in real time. This technology offers a rapid treatment procedure by detecting granulomatous recurrent uveitis, one of the symptom of blau syndrome.

Impact of Macroeconomic factor

Russia-Ukraine war to impact the pharmaceutical companies

Before Russia Invaded Ukraine, projections estimated global economic growth in 2022 would be around 5 percent. The war in Ukraine was a “massive and historic energy shock” to the pharmaceutical industries, slowing down the economic growth in 2022 to just 3.1 percent and further slowing down to 2.2 percent in 2023. The war negatively impacted the pharmaceutical industries creating a revenue loss as Ukraine ranks 61^st among the pharmaceutical products exporter.

Regional Analysis

North America is leading the blau syndrome market

North America has the largest patient pool for Blau syndrome and also represents the largest market share of 61.2%, dominating the regional segment. The region is reported to show rising prevalence of autoimmune diseases and also demand for the treatment for all types of diseases. In addition to this, high healthcare and research and development facilities boosts the market growth of blau syndrome in the region.

Region and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Market Players Analysis

Emerging key players in the market are highly investing in R&D for introduction of novel drugs and therapies for the treatment of blau syndrome. In addition, they are focused on implementing the strategic growth policies to increase their market presence.

Moreover, they are involved in partnerships, collaborations, mergers & acquisitions. Successful launch of diagnostics and drugs, which can diagnose the disease, and reduce the symptoms of blau syndrome respectively, is helping the market to foster during the forecast period.

Top Key Players

• Pfizer
• Salix Pharmaceuticals
• Novartis AG
• Mylan N.V
• Himca pharma plc
• ONCODESIGN
• Amgen Inc
• Abbvie Inc
• Alkem labs
• Accord healthcare
• Zydus Pharmaceuticals
• Centogene AG
• Teva Pharmaceuticals
• Amneal Pharmaceutical Inc

Recent Developments

• In February 2022: Accord healthcare, launched the additional strengths of Hydroxychloroquine Sulfate tablets in dosages of 100mg, 300mg and 400mg, a generic version of Plaquenil and is primarily used to treat rheumatoid arthritis, lupus and malaria.
• In October 2020: Prognos Health, launched the Rare Disease Institute with a focus on improving treatment and diagnosis of rare disease. The company stated, there are various types of rare disease exists in the market and more than thirty million people in the U.S. suffer from these diseases.

Report Scope